Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

Biotech Basics

How a venture capitalist and a biochemist took a risk and changed the shape of science.

Genentech

September 27, 2013 - In 1976, biochemist Dr. Herb Boyer and venture capitalist Bob Swanson met for a beer.

Herb and Bob

At the time they may have seemed like an odd pair, but Herb Boyer had been studying recombinant DNA (rDNA) with geneticist Stanley Cohen. Herb and Stanley knew that they were on the verge of a groundbreaking discovery.

Bob Swanson saw tremendous potential in creating medicines from rDNA. Together they formed a vision of the incredible impact rDNA could have and decided to create build a business off of GEN-etic EN-gineering TECH-nology.

In doing so, they created Genentech and founded the biotechnology industry.

The rDNA technology Herb and Bob were so excited about is sometimes referred to as molecular cloning. Basically, it allows DNA from different sources to be combined which creates new DNA sequences that are not always found in nature.

The protein products of these new sequences can then be identified and isolated. This provides a way of artificially producing proteins, and when proteins can be produced on a large scale, they can be made into medicines.

Here’s what the process looks like:

Diagram

The first protein to be made into an FDA-approved medicine was human insulin for diabetes in 1982. Since then, advances in the science of rDNA technology have allowed us to create increasingly targeted medicines.

For example, therapeutic antibodies are one of the more recent innovations. This class of medicine can be designed to target the underlying biology of disease, including cancer cells or proteins that cause inflammation. Read more on new developments in therapeutic antibodies.

Here's how it works (simplified, of course): 

Diagram

The discovery and development of recombinant DNA launched an industry. It gave scientists a tool to study life and disease at the molecular level. It sparked further discoveries in universities and companies around the world. And, it gave people suffering from the world's most serious conditions new hope.

Today, medicines made from rDNA are becoming an integral part in treating the major public health threats of our time. We are excited to see what tomorrow will bring.

World

Partnering

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Health Equity
  • Advancing Inclusive Research
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Genentech Patient Foundation
  • Understanding Insurance
  • Medicine Information Support
  • Clinical Trial Information
  • Advancing Inclusive Research
  • Our Approach to Pricing
  • Patient Advocacy
  • Create With Us
  • Disease Education
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • —
  • Privacy Policy
  • Terms & Conditions
  • Accessibility
© 2023 Genentech, Inc. All rights reserved. This site is intended for US residents only.